Patents by Inventor Frank Seela

Frank Seela has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8981070
    Abstract: An oligonucleotide-solid phase conjugate, wherein the solid phase is thiophilic and the oligonucleotide comprises at least one thiooxonucleobase according to Formula I, wherein X is CH or N, R1 is H or NH2, --- indicates a covalent bond, and said oligonucleotide is bound to said solid phase via the sulfur atom of said thiooxonucleotide. Also disclosed are methods for producing such conjugate as well as various uses for such oligonucleotide metal conjugate.
    Type: Grant
    Filed: April 19, 2013
    Date of Patent: March 17, 2015
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Simone Budow, Ping Ding, Dieter Heindl, Alfons Nichtl, Frank Seela
  • Publication number: 20130210009
    Abstract: An oligonucleotide-solid phase conjugate, wherein the solid phase is thiophilic and the oligonucleotide comprises at least one thiooxonucleobase according to Formula I, wherein X is CH or N, R1 is H or NH2, --- indicates a covalent bond, and said oligonucleotide is bound to said solid phase via the sulfur atom of said thiooxonucleotide. Also disclosed are methods for producing such conjugate as well as various uses for such oligonucleotide metal conjugate.
    Type: Application
    Filed: April 19, 2013
    Publication date: August 15, 2013
    Applicant: ROCHE DIAGNOSTICS OPERATIONS, INC.
    Inventors: Simone Budow, Ping Ding, Dieter Heindl, Alfons Nichtl, Frank Seela
  • Patent number: 8057997
    Abstract: The present invention is in the field of nucleic acid binding compounds comprising 7-substituted 7-deaza-8aza-2,6-diamino-purine bases, compounds useful for the preparation of such compounds, various uses thereof and methods for the determination of nucleic acids using said compounds in the field of diagnostics.
    Type: Grant
    Filed: April 30, 2007
    Date of Patent: November 15, 2011
    Assignee: Roche Molecular Systems, Inc.
    Inventors: Frank Seela, Frank Bergmann, Herbert Von Der Eltz, Dieter Heindl, Christoph Seidel, Georg Becher
  • Publication number: 20110021365
    Abstract: The present invention is in the field of nucleic acid binding compounds comprising 7-substituted 7-deaza-8aza-2,6-diamino-purine bases, compounds useful for the preparation of such compounds, various uses thereof and methods for the determination of nucleic acids using said compounds in the field of diagnostics.
    Type: Application
    Filed: April 30, 2007
    Publication date: January 27, 2011
    Inventors: Frank Seela, Frank Bergmann, Herbert Von Der Eltz, Dieter Heindl, Christoph Seidel, Georg Becher
  • Patent number: 7847075
    Abstract: Within oligonucleotides, 2-azapurine and especially 2-azaadenine bases form specifically base pairs with guanine. This base pair is of analogous stability as an adenine-thymine but less stable than a guanine-cytosine base pair. Therefore, the incorporation of 2-azaadenine residues into oligonucleotides instead of cytosine leads specifically to hybridization complexes with nucleic acids with homogenous stability. This is useful for the adaptation of the stabilities of different oligonucleotide sequences in all kinds of hybridization techniques, for example in oligomer chip technology.
    Type: Grant
    Filed: August 13, 2009
    Date of Patent: December 7, 2010
    Assignee: Roche Molecular Systems, Inc.
    Inventors: Frank Seela, Helmut Rosemeyer, Enno Schweinberger, Dieter Heindl, Frank Bergmann
  • Publication number: 20100290992
    Abstract: The present invention concerns the field of nanoparticle bioconjugates which form an i-motif or an i-motif related structure (compositions) without or with at least one further nucleic acid binding compound. The i-motif base pairs can be charged or non-charged. Their assembly can be controlled by the pH value or temperature. At least one of these nucleic acid binding compounds has to be attached at least to a nanoparticle. The methods provide compositions used for DNA driven programmable nanoparticle assemblies, electronic circuits, diagnostic detection tools, biosensors, memory storage devices, diagnostic devices for biomolecule sequencing and detection, drug delivery, application in tumour diagnostics and treatment, nanomachines, nanofabrication, nanocatalysis, nanoarrays, and nanoscaled enzyme reactors.
    Type: Application
    Filed: February 9, 2009
    Publication date: November 18, 2010
    Inventors: Frank Seela, Simone Budow, Peter Leonard
  • Publication number: 20090306360
    Abstract: Within oligonucleotides, 2-azapurine and especially 2-azaadenine bases form specifically base pairs with guanine. This base pair is of analogous stability as an adenine-thymine but less stable than a guanine-cytosine base pair. Therefore, the incorporation of 2-azaadenine residues into oligonucleotides instead of cytosine leads specifically to hybridization complexes with nucleic acids with homogenous stability. This is useful for the adaptation of the stabilities of different oligonucleotide sequences in all kinds of hybridization techniques, for example in oligomer chip technology.
    Type: Application
    Filed: August 13, 2009
    Publication date: December 10, 2009
    Applicant: ROCHE MOLECULAR SYSTEMS, INC.
    Inventors: Frank Seela, Helmut Rosemeyer, Enno Schweinberger, Dieter Heindl, Frank Bergmann
  • Patent number: 7612187
    Abstract: Within oligonucleotides 2-azapurine and especially 2-azaadenine bases form specifically base pairs with guanine. This base pair is of analogous stability as an adenine-thymine but less stable than a guanine-cytosine base pair. Therefore, the incorporation of 2-azaadenine residues into oligonucleotides instead of cytosine leads specifically to hybridization complexes with nucleic acids with homogenous stability. This is useful for the adaptation of the stabilities of different oligonucleotide sequences in all kinds of hybridization techniques, for example in oligomer chip technology.
    Type: Grant
    Filed: May 25, 2006
    Date of Patent: November 3, 2009
    Assignee: Roche Diagnostics, GmbH
    Inventors: Frank Seela, Helmut Rosemeyer, Enno Schweinberger, Dieter Heindl, Frank Bergmann
  • Patent number: 7566775
    Abstract: The present invention is directed to a nucleic acid binding compound comprising N8- or C8-linked purine bases or structurally related heterocycles, a compound useful for the preparation of such compound, a binding product of this nucleic acid binding compound with a nucleic acid, a method for the determination of a nucleic acid using said compound, and several uses of 8-linked purine bases and structurally related heterocycles. Compounds according to the present invention have advantageous properties when used in hybridization methods.
    Type: Grant
    Filed: January 23, 2006
    Date of Patent: July 28, 2009
    Assignee: Roche Molecular Systems, Inc.
    Inventors: Frank Seela, Frank Bergmann, Dieter Heindl, Herbert Von der Eltz
  • Patent number: 7238795
    Abstract: The present invention is in the field of nucleic acid binding compounds comprising 7-substituted 7-deaza-8aza-2,6-diamino-purine bases, compounds useful for the preparation of such compounds, various uses thereof and methods for the determination of nucleic acids using said compounds in the field of diagnostics.
    Type: Grant
    Filed: July 31, 2001
    Date of Patent: July 3, 2007
    Assignee: Roche Molecular Systems, Inc.
    Inventors: Frank Seela, Frank Bergmann, Herbert Von Der Eltz, Dieter Heindl, Christoph Seidel, Georg Becher
  • Patent number: 7169553
    Abstract: Within oligonucleotides 2-azapurine and especially 2-azaadenine bases form specifically base pairs with guanine. This base pair is of analogous stability as an adenine-thymine but less stable than a guanine-cytosine base pair. Therefore, the incorporation of 2-azaadenine residues into oligonucleotides instead of cytosine leads specifically to hybridization complexes with nucleic acids with homogenous stability. This is useful for the adaptation of the stabilities of different oligonucleotide sequences in all kinds of hybridization techniques, for example in oligomer chip technology.
    Type: Grant
    Filed: August 28, 2000
    Date of Patent: January 30, 2007
    Assignee: Roche Diagnostics, GmbH
    Inventors: Frank Seela, Helmut Rosenmeyer, Enno Schweinberger, Dieter Heindl, Frank Bergmann
  • Publication number: 20070015725
    Abstract: Within oligonucleotides 2-azapurine and especially 2-azaadenine bases form specifically base pairs with guanine. This base pair is of analogous stability as an adenine-thymine but less stable than a guanine-cytosine base pair. Therefore, the incorporation of 2-azaadenine residues into oligonucleotides instead of cytosine leads specifically to hybridization complexes with nucleic acids with homogenous stability. This is useful for the adaptation of the stabilities of different oligonucleotide sequences in all kinds of hybridization techniques, for example in oligomer chip technology.
    Type: Application
    Filed: May 25, 2006
    Publication date: January 18, 2007
    Applicant: Roche Diagnostics, GMBH
    Inventors: Frank Seela, Helmut Rosemeyer, Enno Schweinberger, Dieter Heindl, Frank Bergmann
  • Publication number: 20060135462
    Abstract: The present invention is directed to a nucleic acid binding compound comprising N8- or C8-linked purine bases or structurally related heterocycles, a compound useful for the preparation of such compound, a binding product of this nucleic acid binding compound with a nucleic acid, a method for the determination of a nucleic acid using said compound, and several uses of 8-linked purine bases and structurally related heterocycles. Compounds according to the present invention have advantageous properties when used in hybridization methods.
    Type: Application
    Filed: January 23, 2006
    Publication date: June 22, 2006
    Applicant: ROCHE MOLECULAR SYSTEMS, INC.
    Inventors: Frank Seela, Frank Bergmann, Dieter Heindl, Herbert Von Der Eltz
  • Patent number: 7063945
    Abstract: The present invention is directed to a nucleic acid binding compound comprising N8- or C8-linked purine bases or structurally related heterocycles, a compound useful for the preparation of such compound, a binding product of this nucleic acid binding compound with a nucleic acid, a method for the determination of a nucleic acid using said compound, and several uses of 8-linked purine bases and structurally related heterocycles. Compounds according to the present invention have advantageous properties when used in hybridization methods.
    Type: Grant
    Filed: March 27, 2001
    Date of Patent: June 20, 2006
    Assignee: Roche Molecular Systems, Inc
    Inventors: Frank Seela, Harald Debelak, Frank Bergmann, Dieter Heindl, Herbert Von Der Eltz
  • Publication number: 20060040944
    Abstract: This invention is directed to a method for treating a host, especially a human, infected with hepatitis C, flavivirus and/or pestivirus, comprising administering to that host an effective amount of an anti-flavivirus or anti-pestivirus, biologically active compound has a 5-aza-7-deazapurine moiety. The 5-aza-7-deazapurine moiety may be substituted or unsubstituted, and may comprise a nucleoside analogue, or a salt or prodrug thereof. The compound of the present invention may be administered alone or in combination with another anti-hepatitis C, anti-flavivirus and/or anti-pestivirus agent.
    Type: Application
    Filed: June 23, 2005
    Publication date: February 23, 2006
    Inventors: Gilles Gosselin, Frank Seela, Paolo La Colla, Richard Storer, David Dukhan, Frederic Leroy
  • Patent number: 6987177
    Abstract: Modified oligonucleotides which possess at least one substituted 7-deazapurine base form more stable hybridization complexes with nucleic acids than unsubstituted analogs. They are useful as inhibitors of gene expression, as probes for detecting nucleic acids, as aids in molecular biology and as pharmaceuticals or diagnostic agents. Processes for preparing them are provided.
    Type: Grant
    Filed: August 19, 2002
    Date of Patent: January 17, 2006
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Frank Seela, Horst Thomas
  • Publication number: 20040214221
    Abstract: Subjects of the inventions are methods for enzymatic DNA labeling. Nucleotides modified to carry functional or detectable groups are incorporated into newly synthesized DNA by DNA polymerases. DNA is synthesized from modified nuleoside triphosphates by DNA polymerases such that the newly synthesized DNA consists exclusively of modified nucleotides or contains modified nucleotides in high density.
    Type: Application
    Filed: May 19, 2004
    Publication date: October 28, 2004
    Inventors: Klaus Muehlegger, Bernhard Angerer, Frank Seela, Waltraud Ankenbauer, Martin Augustin, Karin Gumbiowski, Matthias Zulauf
  • Publication number: 20040171820
    Abstract: The present invention is directed to a nucleic acid binding compound comprising N8- or C8-linked purine bases or structurally related heterocycles, a compound useful for the preparation of such compound, a binding product of this nucleic acid binding compound with a nucleic acid, a method for the determination of a nucleic acid using said compound, and several uses of 8-linked purine bases and structurally related heterocycles. Compounds according to the present invention have advantageous properties when used in hybridization methods.
    Type: Application
    Filed: September 10, 2002
    Publication date: September 2, 2004
    Inventors: Frank Seela, Harald Debelak, Frank Bergmann, Dieter Heindl, Herbert Von Der Eltz
  • Publication number: 20030198982
    Abstract: The present invention is in the field of nucleic acid binding compounds comprising 7-substituted 7-deaza-8aza-2,6-diamino-purine bases, compounds useful for the preparation of such compounds, various uses thereof and methods for the determination of nucleic acids using said compounds in the field of diagnostics.
    Type: Application
    Filed: January 21, 2003
    Publication date: October 23, 2003
    Inventors: Frank Seela, Frank Bergmann, Herbert Von Der Eltz, Dieter Heindl, Christoph Seidel, Georg Becher
  • Publication number: 20030096981
    Abstract: Modified oligonucleotides which possess at least one substituted 7-deazapurine base form more stable hybridization complexes with nucleic acids than unsubstituted analogs. They are useful as inhibitors of gene expression, as probes for detecting nucleic acids, as aids in molecular biology and as pharmaceuticals or diagnostic agents. Processes for preparing them are provided.
    Type: Application
    Filed: August 19, 2002
    Publication date: May 22, 2003
    Inventors: Frank Seela, Horst Thomas